Related references
Note: Only part of the references are listed.New drugs for the treatment of diabetes - Part II: Incretin-based therapy and beyond
Silvio E. Inzucchi et al.
CIRCULATION (2008)
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
Kenji Nonaka et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Pleiotropic effects of thiazolidinediones
C. V. Rizos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN) and their related enzymes as possible targets in the treatment of skin diseases
Anja Thielitz et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Management of Hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2008)
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat-fed mice
Benjamin J. Lamont et al.
DIABETES (2008)
The importance of treating multiple cardiometabolic in patients with Type 2 diabetes
Dimitri P. Mikhailidis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Sitagliptin with metformin: Profile of a combination for the treatment of type 2 diabetes
Baptist Gallwitz
DRUGS OF TODAY (2007)
Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus
Shari Bolen et al.
ANNALS OF INTERNAL MEDICINE (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes
A. Schweizer et al.
DIABETIC MEDICINE (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
Renee E. Amori et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
Dennis Kim et al.
DIABETES CARE (2007)
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
Markolf Hanefeld et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
F. Xavier Pi-Sunyer et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes
R. Brazg et al.
DIABETES OBESITY & METABOLISM (2007)
Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
S. Dejager et al.
HORMONE AND METABOLIC RESEARCH (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects
Goutam C. Mistry et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects
Rajesh Krishna et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
R. Scott et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
Emanuele Bosi et al.
DIABETES CARE (2007)
Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles
Irene F. Gazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation
Dirk Reinhold et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) -: A novel approach for the treatment of inflammatory bowel disease
Ute Bank et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Circulating levels of soluble CD26 are associated with phobic anxiety in women
Enzo Emanuele et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2006)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function
Sabine Wrenger et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2006)
G-CSF- and GM-CSF-induced upregulation of CD26 peptidase downregulates the functional chemotactic response of CD34+CD38- human cord blood hematopoietic cells
Kent W. Christopherson et al.
EXPERIMENTAL HEMATOLOGY (2006)
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
R. E. Pratley et al.
HORMONE AND METABOLIC RESEARCH (2006)
Inhibition of CD26 peptidase activity significantly improves engraftment of retrovirally transduced hematopoietic progenitors
C Tian et al.
GENE THERAPY (2006)
Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures
EN Liberopoulos et al.
CURRENT DRUG TARGETS (2006)
CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity
R Guieu et al.
BEHAVIOURAL BRAIN RESEARCH (2006)
Extraenzymatic functions of the dipeptidyl peptidase IV-related proteins DP8 and DP9 in cell adhesion, migration and apoptosis
Denise M. T. Yu et al.
FEBS JOURNAL (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma
I Gazi et al.
CLINICAL CHEMISTRY (2005)
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
S Ristic et al.
DIABETES OBESITY & METABOLISM (2005)
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes - A randomized trial
RJ Heine et al.
ANNALS OF INTERNAL MEDICINE (2005)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders
MD Gorrell
CLINICAL SCIENCE (2005)
Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26):: Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy
T Kelly
DRUG RESISTANCE UPDATES (2005)
Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - Results of a pilot study
KG Parhofer et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2005)
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors
T Hansotia et al.
DIABETES (2004)
Incretins, insulin secretion and Type 2 diabetes mellitus
T Vilsboll et al.
DIABETOLOGIA (2004)
Modulation of hematopoietic stem cell homing and engraftment by CD26
KW Christopherson et al.
SCIENCE (2004)
Dipeptidyl peptidase IV inhibitors for the treatment of diabetes
AE Weber
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
Cell-surface peptidases
R Mentlein
INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 235 (2004)
Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system
PL Brubaker et al.
ENDOCRINOLOGY (2004)
Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells
UV Wesley et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030
S Wild et al.
DIABETES CARE (2004)
Thiazolidinediones and blood lipids in type 2 diabetes
JPH van Wijk et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker
DIABETES CARE (2003)
Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies
B Jones et al.
BLOOD (2003)
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
JJ Meier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1α-mediated chemotaxis of human cord blood CD34+ progenitor cells
KW Christopherson et al.
JOURNAL OF IMMUNOLOGY (2002)
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes
P Raskin et al.
DIABETES CARE (2001)
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, placebo-controlled study
MS Kipnes et al.
AMERICAN JOURNAL OF MEDICINE (2001)
Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8
CA Abbott et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2000)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
D Marguet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus - A randomized controlled trial
V Fonseca et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
